CN102762743A - 用于心血管疾病的诊断和分类的生物标记物检验 - Google Patents
用于心血管疾病的诊断和分类的生物标记物检验 Download PDFInfo
- Publication number
- CN102762743A CN102762743A CN2010800635211A CN201080063521A CN102762743A CN 102762743 A CN102762743 A CN 102762743A CN 2010800635211 A CN2010800635211 A CN 2010800635211A CN 201080063521 A CN201080063521 A CN 201080063521A CN 102762743 A CN102762743 A CN 102762743A
- Authority
- CN
- China
- Prior art keywords
- mir
- classification
- affinity tag
- mirna
- data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 63
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 41
- 238000003745 diagnosis Methods 0.000 title claims description 20
- 238000003556 assay Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 206
- 108091070501 miRNA Proteins 0.000 claims abstract description 149
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 88
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 88
- 230000036996 cardiovascular health Effects 0.000 claims abstract description 25
- 239000002679 microRNA Substances 0.000 claims abstract description 25
- 239000000523 sample Substances 0.000 claims description 134
- 238000004422 calculation algorithm Methods 0.000 claims description 82
- 201000001320 Atherosclerosis Diseases 0.000 claims description 77
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 74
- 238000012360 testing method Methods 0.000 claims description 73
- 238000004458 analytical method Methods 0.000 claims description 66
- 239000012472 biological sample Substances 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 46
- 229940079593 drug Drugs 0.000 claims description 37
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 33
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 33
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 claims description 32
- -1 miR-331.3p Proteins 0.000 claims description 30
- 208000010125 myocardial infarction Diseases 0.000 claims description 29
- 102000019034 Chemokines Human genes 0.000 claims description 25
- 108010012236 Chemokines Proteins 0.000 claims description 25
- 230000004913 activation Effects 0.000 claims description 24
- 230000007211 cardiovascular event Effects 0.000 claims description 24
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 23
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 23
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 23
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 23
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 23
- 210000000222 eosinocyte Anatomy 0.000 claims description 23
- 239000012474 protein marker Substances 0.000 claims description 23
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims description 22
- 101710112538 C-C motif chemokine 27 Proteins 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 19
- 102000011690 Adiponectin Human genes 0.000 claims description 18
- 108010076365 Adiponectin Proteins 0.000 claims description 18
- 108090000171 Interleukin-18 Proteins 0.000 claims description 17
- 102000003810 Interleukin-18 Human genes 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 238000004393 prognosis Methods 0.000 claims description 15
- 238000013442 quality metrics Methods 0.000 claims description 11
- 238000002493 microarray Methods 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 238000013480 data collection Methods 0.000 claims description 8
- 208000007814 Unstable Angina Diseases 0.000 claims description 7
- 230000036772 blood pressure Effects 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000000391 smoking effect Effects 0.000 claims description 7
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 5
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 5
- 238000007637 random forest analysis Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 208000035868 Vascular inflammations Diseases 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 108091050874 miR-19a stem-loop Proteins 0.000 claims description 3
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 claims description 3
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 claims description 3
- 238000012706 support-vector machine Methods 0.000 claims description 3
- 238000010801 machine learning Methods 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 10
- 101000880339 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Sterigmatocystin biosynthesis fatty acid synthase subunit alpha Proteins 0.000 claims 4
- 108091031326 miR-15b stem-loop Proteins 0.000 claims 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 3
- 108091063340 miR-497 stem-loop Proteins 0.000 claims 3
- 108091050734 miR-652 stem-loop Proteins 0.000 claims 3
- 108091076732 miR-99a stem-loop Proteins 0.000 claims 3
- 108091064318 miR-99a-1 stem-loop Proteins 0.000 claims 3
- 108091086202 miR-99a-2 stem-loop Proteins 0.000 claims 3
- 108091028066 Mir-126 Proteins 0.000 claims 2
- 108091062170 Mir-22 Proteins 0.000 claims 2
- 108091007423 let-7b Proteins 0.000 claims 2
- 108091092825 miR-24 stem-loop Proteins 0.000 claims 2
- 108091032978 miR-24-3 stem-loop Proteins 0.000 claims 2
- 108091064025 miR-24-4 stem-loop Proteins 0.000 claims 2
- 108091088477 miR-29a stem-loop Proteins 0.000 claims 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims 2
- 108091047189 miR-29c stem-loop Proteins 0.000 claims 2
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims 2
- 108091063344 miR-30b stem-loop Proteins 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 210000004251 human milk Anatomy 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 claims 1
- 238000012549 training Methods 0.000 description 96
- 230000014509 gene expression Effects 0.000 description 54
- 238000001228 spectrum Methods 0.000 description 31
- 238000009826 distribution Methods 0.000 description 27
- 238000002790 cross-validation Methods 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 230000003143 atherosclerotic effect Effects 0.000 description 22
- 238000003066 decision tree Methods 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 238000005259 measurement Methods 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 20
- 108010002616 Interleukin-5 Proteins 0.000 description 18
- 102100039897 Interleukin-5 Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 102100026019 Interleukin-6 Human genes 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000007477 logistic regression Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 238000007405 data analysis Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000007619 statistical method Methods 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012491 analyte Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000010224 classification analysis Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100023688 Eotaxin Human genes 0.000 description 3
- 101710139422 Eotaxin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 108091027943 miR-16 stem-loop Proteins 0.000 description 3
- 108091086416 miR-192 stem-loop Proteins 0.000 description 3
- 108091032902 miR-93 stem-loop Proteins 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 108091028049 Mir-221 microRNA Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013145 classification model Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 108091050724 let-7b stem-loop Proteins 0.000 description 2
- 108091030917 let-7b-1 stem-loop Proteins 0.000 description 2
- 108091082924 let-7b-2 stem-loop Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000011880 melting curve analysis Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 108091064399 miR-10b stem-loop Proteins 0.000 description 2
- 108091044988 miR-125a stem-loop Proteins 0.000 description 2
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 2
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 2
- 108091080321 miR-222 stem-loop Proteins 0.000 description 2
- 108091061970 miR-26a stem-loop Proteins 0.000 description 2
- 108091034121 miR-92a stem-loop Proteins 0.000 description 2
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 2
- 238000012821 model calculation Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000005011 time of flight secondary ion mass spectroscopy Methods 0.000 description 2
- 238000002042 time-of-flight secondary ion mass spectrometry Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000610206 Homo sapiens Pappalysin-1 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 108091007774 MIR107 Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108091046841 MiR-150 Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100040156 Pappalysin-1 Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 206010067130 Spastic diplegia Diseases 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108091037473 miR-103 stem-loop Proteins 0.000 description 1
- 108091045790 miR-106b stem-loop Proteins 0.000 description 1
- 108091047641 miR-186 stem-loop Proteins 0.000 description 1
- 108091049679 miR-20a stem-loop Proteins 0.000 description 1
- 108091039792 miR-20b stem-loop Proteins 0.000 description 1
- 108091055878 miR-20b-1 stem-loop Proteins 0.000 description 1
- 108091027746 miR-20b-2 stem-loop Proteins 0.000 description 1
- 108091055059 miR-30c stem-loop Proteins 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000012627 multivariate algorithm Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Databases & Information Systems (AREA)
- Theoretical Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Primary Health Care (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28512109P | 2009-12-09 | 2009-12-09 | |
| US61/285,121 | 2009-12-09 | ||
| PCT/US2010/059781 WO2011072177A2 (en) | 2009-12-09 | 2010-12-09 | Biomarker assay for diagnosis and classification of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102762743A true CN102762743A (zh) | 2012-10-31 |
Family
ID=43587661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800635211A Pending CN102762743A (zh) | 2009-12-09 | 2010-12-09 | 用于心血管疾病的诊断和分类的生物标记物检验 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20110144914A1 (enExample) |
| EP (1) | EP2510116A2 (enExample) |
| JP (1) | JP2013513387A (enExample) |
| CN (1) | CN102762743A (enExample) |
| AU (1) | AU2010328019A1 (enExample) |
| CA (1) | CA2783536A1 (enExample) |
| WO (1) | WO2011072177A2 (enExample) |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN103233007A (zh) * | 2013-02-05 | 2013-08-07 | 中国科学院广州生物医药与健康研究院 | hsa-miR-545miRNA及其应用 |
| CN103642914A (zh) * | 2013-11-29 | 2014-03-19 | 李春英 | 与恶性黑素瘤相关的血浆/血清循环microRNA标志物及其应用 |
| CN104017806A (zh) * | 2014-05-08 | 2014-09-03 | 复旦大学 | microRNA及其在制备活动性结核病检测试剂中的应用 |
| CN104278105A (zh) * | 2014-11-07 | 2015-01-14 | 雷桅 | 一种检测冠心病的血清学生物标志物miR-19a及其用途 |
| CN104357554A (zh) * | 2013-11-26 | 2015-02-18 | 上海中医药大学附属岳阳中西医结合医院 | 微小核苷酸has-miR939在高血压诊断中的应用 |
| CN105486878A (zh) * | 2016-01-22 | 2016-04-13 | 徐超 | 一种临床个体化组合用药的筛选系统及其方法 |
| CN105713972A (zh) * | 2016-03-16 | 2016-06-29 | 上海中医药大学 | miRNA在制备药物性心脏病生物标志物中的用途 |
| CN105993016A (zh) * | 2014-02-04 | 2016-10-05 | 奥普蒂马塔公司 | 用于预测医疗效果的方法和系统 |
| CN106609301A (zh) * | 2015-10-26 | 2017-05-03 | 北京大学人民医院 | 一种辅助诊断1型糖尿病的试剂盒 |
| CN107194138A (zh) * | 2016-01-31 | 2017-09-22 | 青岛睿帮信息技术有限公司 | 一种基于体检数据建模的空腹血糖预测方法 |
| CN107422126A (zh) * | 2011-09-30 | 2017-12-01 | 私募蛋白质体公司 | 心血管危险事件预测及其用途 |
| CN107710205A (zh) * | 2015-04-14 | 2018-02-16 | 优比欧迈公司 | 用于心血管疾病状况的微生物组来源的表征、诊断和治疗的方法及系统 |
| CN108004316A (zh) * | 2018-01-09 | 2018-05-08 | 青岛大学 | 用于预测急性心肌梗死风险的试剂盒 |
| CN108376564A (zh) * | 2018-02-06 | 2018-08-07 | 天津艾登科技有限公司 | 基于随机森林算法的疾病诊断并发症识别方法及系统 |
| CN108492272A (zh) * | 2018-03-26 | 2018-09-04 | 西安交通大学 | 基于注意力模型及多任务神经网络的心血管易损斑块识别方法及系统 |
| CN108700596A (zh) * | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| CN108728437A (zh) * | 2018-05-25 | 2018-11-02 | 中国人民解放军陆军军医大学 | 促进骨骼肌损伤修复的寡核苷酸、药物及应用 |
| CN108803994A (zh) * | 2018-06-14 | 2018-11-13 | 四川和生视界医药技术开发有限公司 | 视网膜血管的管理方法及视网膜血管的管理装置 |
| TWI641963B (zh) * | 2017-07-07 | 2018-11-21 | 長庚醫療財團法人林口長庚紀念醫院 | Method for screening coronary heart disease by cardiovascular marker and mechanical learning algorithm |
| CN108998514A (zh) * | 2018-08-20 | 2018-12-14 | 青岛大学 | miRNA-378及其抑制剂的应用和应用其的产品 |
| CN109411015A (zh) * | 2018-09-28 | 2019-03-01 | 深圳裕策生物科技有限公司 | 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质 |
| CN109416361A (zh) * | 2016-03-31 | 2019-03-01 | 雅培制药有限公司 | 用于估计急性冠状动脉综合征的风险的基于决策树的系统和方法 |
| CN109985243A (zh) * | 2017-12-29 | 2019-07-09 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
| CN110651186A (zh) * | 2017-01-06 | 2020-01-03 | 科多迪克斯有限责任公司 | 用于遗传物质分析的系统、方法和设备 |
| CN110799648A (zh) * | 2017-06-29 | 2020-02-14 | 东丽株式会社 | 用于检测肺癌的试剂盒、装置和方法 |
| CN111154870A (zh) * | 2019-08-05 | 2020-05-15 | 江苏省肿瘤医院 | 一种鼻咽癌转移诊断和/或预后评估的生物标记 |
| CN111718991A (zh) * | 2020-07-03 | 2020-09-29 | 西安交通大学医学院第一附属医院 | 血浆miRNA分子标志物在诊断代谢综合征中的应用 |
| CN111886630A (zh) * | 2018-02-20 | 2020-11-03 | 密歇根大学董事会 | 用于细胞和亚细胞形态学建模和分类的三维细胞和组织图像分析 |
| US10854314B2 (en) | 2014-05-15 | 2020-12-01 | Codondex Llc | Systems, methods, and devices for analysis of genetic material |
| CN112509700A (zh) * | 2021-02-05 | 2021-03-16 | 中国医学科学院阜外医院 | 稳定型冠心病的风险预测方法及装置 |
| CN112530595A (zh) * | 2020-12-21 | 2021-03-19 | 无锡市第二人民医院 | 一种基于多分支链式神经网络的心血管疾病分类方法和装置 |
| US11017881B2 (en) | 2014-05-15 | 2021-05-25 | Codondex Llc | Systems, methods, and devices for analysis of genetic material |
| US11041866B2 (en) | 2010-08-13 | 2021-06-22 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
| US11221340B2 (en) | 2010-07-09 | 2022-01-11 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| CN114058696A (zh) * | 2020-07-29 | 2022-02-18 | 四川大学华西医院 | miR-519e-5p作为甲状腺乳头状癌远处转移检测或治疗靶点中的用途 |
| CN114113624A (zh) * | 2020-08-28 | 2022-03-01 | 香港城市大学深圳研究院 | 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置 |
| CN115901901A (zh) * | 2022-01-15 | 2023-04-04 | 山东师范大学 | TiO2-MoO3纳米阵列及基于其的miR-145-3p早检传感芯片及其应用 |
| CN116334206A (zh) * | 2022-11-09 | 2023-06-27 | 上海长征医院 | miR-541在制备肝纤维化/肝硬化无创诊断及预后评估试剂盒中的应用 |
| CN117737262A (zh) * | 2024-02-21 | 2024-03-22 | 山东第一医科大学(山东省医学科学院) | 一种miRNA标志物在制备鉴别体液斑产品中的应用 |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| WO2011056186A1 (en) * | 2009-10-26 | 2011-05-12 | Albert Einstein College Of Medicine Of Yeshiva University | Microrna affinity assay and uses thereof |
| WO2011131354A1 (en) * | 2010-04-20 | 2011-10-27 | Febit Holding Gmbh | Complex mirna sets as novel biomarkers for an acute coronary syndrome |
| WO2011154689A1 (en) * | 2010-06-07 | 2011-12-15 | King's College London | Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection |
| TW201231671A (en) * | 2011-01-28 | 2012-08-01 | Univ Kaohsiung Medical | Method and kit for in vitro diagnosis of atherosclerosis |
| EP2714934B1 (en) * | 2011-05-24 | 2018-09-19 | Rosetta Genomics Ltd | Methods and compositions for determining heart failure or a risk of heart failure |
| US9708643B2 (en) * | 2011-06-17 | 2017-07-18 | Affymetrix, Inc. | Circulating miRNA biomaker signatures |
| AU2011375306A1 (en) | 2011-08-12 | 2014-02-27 | Alfred Health | Method for diagnosis, prognosis or treatment of acute coronary syndrome (ACS) comprising measurement of plasma concentration of macrophage migration inhibitory factor (MIF) |
| EP2771482A1 (en) * | 2011-10-27 | 2014-09-03 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for the treatment and diagnosis of atherosclerosis |
| CN103103189B (zh) * | 2011-11-14 | 2015-06-03 | 中国科学院上海生命科学研究院 | 过表达单一MicroRNA成熟体序列的新方法 |
| CN103160507B (zh) * | 2011-12-19 | 2017-05-24 | 上海交通大学医学院附属新华医院 | 检测肝硬化的miRNA血清标志物及其应用 |
| ITRM20110685A1 (it) | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
| US9726668B2 (en) | 2012-02-09 | 2017-08-08 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| US10417575B2 (en) * | 2012-12-14 | 2019-09-17 | Microsoft Technology Licensing, Llc | Resource allocation for machine learning |
| DE102012101557A1 (de) * | 2012-02-27 | 2013-08-29 | Charité Universitätsmedizin Berlin | Verwendung von microRNAs oder Genen als Marker zur Identifizierung, Diagnose und Therapie einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens |
| CN102708384B (zh) * | 2012-06-04 | 2014-01-29 | 西南交通大学 | 一种基于随机蕨的自举弱学习方法及其分类器 |
| US9002769B2 (en) * | 2012-07-03 | 2015-04-07 | Siemens Aktiengesellschaft | Method and system for supporting a clinical diagnosis |
| US9336302B1 (en) | 2012-07-20 | 2016-05-10 | Zuci Realty Llc | Insight and algorithmic clustering for automated synthesis |
| CN102839172B (zh) * | 2012-08-24 | 2013-09-25 | 中国医科大学附属第一医院 | HIV感染疾病进展分子标志物miR-503 |
| US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
| US9996889B2 (en) * | 2012-10-01 | 2018-06-12 | International Business Machines Corporation | Identifying group and individual-level risk factors via risk-driven patient stratification |
| EP4365793A3 (en) * | 2013-03-04 | 2024-07-31 | Board Of Regents Of the University Of Texas System | System and method for determining triage categories |
| US20160076026A1 (en) * | 2013-03-15 | 2016-03-17 | The Hospital For Sick Children | Diagnostic and therapeutic methods relating to microrna-144 |
| CN103205505B (zh) * | 2013-05-03 | 2014-11-05 | 周玲 | 一种诊断妊娠糖尿病的microRNA分子标志物及其检测试剂盒 |
| KR20150007468A (ko) * | 2013-07-11 | 2015-01-21 | (의료)길의료재단 | 임상의사결정 지원방법 및 그 장치 |
| US9953417B2 (en) * | 2013-10-04 | 2018-04-24 | The University Of Manchester | Biomarker method |
| US10817791B1 (en) * | 2013-12-31 | 2020-10-27 | Google Llc | Systems and methods for guided user actions on a computing device |
| US10138717B1 (en) * | 2014-01-07 | 2018-11-27 | Novi Labs, LLC | Predicting well performance with feature similarity |
| AU2015229270B2 (en) | 2014-03-12 | 2020-12-24 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| CN106661635B (zh) | 2014-06-26 | 2021-05-28 | 西奈山伊坎医学院 | 通过分析预示性基因集诊断亚临床和临床的急性排异的方法 |
| AU2015279621B2 (en) * | 2014-06-26 | 2021-04-08 | Icahn School Of Medicine At Mount Sinai | Methods for diagnosing risk of renal allograft fibrosis and rejection |
| EP3189337A4 (en) | 2014-07-07 | 2018-04-25 | Veramarx, Inc. | Biomarker signatures for lyme disease and methods of use thereof |
| CA3190715A1 (en) | 2014-08-14 | 2016-02-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| US10801066B2 (en) | 2014-09-05 | 2020-10-13 | American University Of Beirut | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger RNA |
| WO2016048388A1 (en) | 2014-09-26 | 2016-03-31 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| CN107209184B (zh) | 2014-12-11 | 2020-04-24 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| JP6782405B2 (ja) * | 2014-12-15 | 2020-11-11 | 学校法人 久留米大学 | 腎性貧血のバイオマーカーとしての赤血球admaの使用 |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| KR101903526B1 (ko) * | 2015-08-19 | 2018-10-05 | 한국전자통신연구원 | 바이오 물질의 농도를 기반으로 하는 질환 예측 장치 및 그것의 질환 예측 방법 |
| DE102015216782B3 (de) * | 2015-09-02 | 2017-01-26 | Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh | Verwendung von im Blutserum oder Blutplasma zirkulierenden microRNAs zur Identifikation biopsiepflichtiger Patienten und als Marker zur Differentialdiagnose einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens |
| US11191490B2 (en) * | 2015-12-02 | 2021-12-07 | Siemens Healthcare Gmbh | Personalized assessment of patients with acute coronary syndrome |
| EA201600076A1 (ru) * | 2015-12-30 | 2017-07-31 | Андрей Владимирович ТИТОВ | Способ оценки состояния организма по образцам биологической жидкости, получаемой неинвазивно |
| US10725038B2 (en) | 2016-01-06 | 2020-07-28 | Veramarx, Inc. | Biomarker signatures for lyme disease differentiation and methods of use thereof |
| EP3196317A1 (en) | 2016-01-21 | 2017-07-26 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Predictive methods of atherosclerosis and stenosis |
| FR3047013A1 (fr) * | 2016-01-22 | 2017-07-28 | Univ Montpellier | Procede de classification d'un echantillon biologique. |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN108699609A (zh) | 2016-03-03 | 2018-10-23 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
| EP4141448A1 (en) * | 2016-07-10 | 2023-03-01 | MeMed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
| US20180166170A1 (en) * | 2016-12-12 | 2018-06-14 | Konstantinos Theofilatos | Generalized computational framework and system for integrative prediction of biomarkers |
| WO2018140568A1 (en) * | 2017-01-27 | 2018-08-02 | Becton, Dickinson And Company | Vertical flow assay device for detecting glucose concentration in a fluid sample |
| EP3688466A4 (en) * | 2017-09-30 | 2021-05-19 | Alfred Health | FORECAST PROCEDURE |
| JP7372251B2 (ja) * | 2017-11-02 | 2023-10-31 | プリベンシオ,インコーポレイテッド | 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム |
| CN108070650B (zh) * | 2018-02-09 | 2021-02-12 | 深圳承启生物科技有限公司 | 外泌体中microRNA在诊断缺血性脑卒中疾病的用途 |
| BR112020019972A2 (pt) | 2018-04-16 | 2021-01-05 | Icahn School Of Medicine At Mount Sinai | Métodos para identificar um receptor de aloenxerto renal e para identificar um receptor de aloenxerto renal em risco de rejeição aguda do aloenxerto antes do transplante, kit para identificar receptores de aloenxerto renal e método para selecionar um paciente com aloenxerto renal |
| WO2019217714A1 (en) * | 2018-05-09 | 2019-11-14 | The General Hospital Corporation | Determination and reduction of risk of sudden cardiac death |
| RU2677280C1 (ru) * | 2018-05-17 | 2019-01-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики многососудистого атеросклеротического поражения коронарных артерий у больных ишемической болезнью сердца при абдоминальном ожирении |
| US12292451B2 (en) * | 2018-06-08 | 2025-05-06 | Cleveland Clinic Foundation | ApoA1 exchange rate assays in serum |
| CN109009222A (zh) * | 2018-06-19 | 2018-12-18 | 杨成伟 | 面向心脏病类型和严重程度的智能评估诊断方法及系统 |
| CN108796070B (zh) * | 2018-07-16 | 2022-09-30 | 辽宁中医药大学 | miR-125a-3p在制备心血管疾病诊断试剂盒中的用途 |
| EP3870030A4 (en) * | 2018-10-23 | 2022-08-03 | Blackthorn Therapeutics, Inc. | SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS |
| US11928985B2 (en) * | 2018-10-30 | 2024-03-12 | International Business Machines Corporation | Content pre-personalization using biometric data |
| KR102165841B1 (ko) * | 2018-11-05 | 2020-10-14 | 순천향대학교 산학협력단 | 당뇨병 진단을 위한 마이크로RNA let-7b 또는 마이크로RNA-664a 바이오마커 및 이의 용도 |
| CN113271849B (zh) * | 2018-11-29 | 2024-08-30 | 私募蛋白质体操作有限公司 | 结合类别不平衡集降采样与生存分析的疾病风险确定方法 |
| CN110229893A (zh) * | 2019-02-04 | 2019-09-13 | 金华市中心医院 | 用于诊断颈动脉粥样硬化斑块的miRNAs标志物及其应用 |
| CN110082536B (zh) * | 2019-04-17 | 2022-06-10 | 广州医科大学附属肿瘤医院 | 一种乳腺癌细胞标志物细胞因子群及其应用 |
| US11030743B2 (en) * | 2019-05-16 | 2021-06-08 | Tencent America LLC | System and method for coronary calcium deposits detection and labeling |
| EP3990664A1 (en) * | 2019-06-26 | 2022-05-04 | Westfälische Wilhelms-Universität Münster | Method for establishing an individual physical activity program for a subject for reducing an individual risk of the subject for developing a cardiovascular disease |
| EP4042427A4 (en) * | 2019-10-02 | 2024-03-13 | Endpoint Health Inc. | BIOMARKER TABLES TO GUIDE DYSREGULATED HOST RESPONSES THERAPY |
| WO2021090182A1 (en) * | 2019-11-04 | 2021-05-14 | Oxford University Innovation Limited | Identification and characterisation of herbicides and plant growth regulators |
| CN111275125A (zh) * | 2020-02-10 | 2020-06-12 | 东华大学 | 一种面向低秩图像特征分析的类别标签恢复方法 |
| US11058710B1 (en) | 2020-02-14 | 2021-07-13 | Dasman Diabetes Institute | MicroRNA ANGPTL3 inhibitor |
| EP3971909A1 (en) * | 2020-09-21 | 2022-03-23 | Thorsten Kaiser | Method for predicting markers which are characteristic for at least one medical sample and/or for a patient |
| CN112280845A (zh) * | 2020-09-22 | 2021-01-29 | 山东大学第二医院 | miR-328-3p在制备脑梗死及脑缺血再灌注预后预测试剂中的应用 |
| CN114520054A (zh) * | 2020-11-18 | 2022-05-20 | 英业达科技有限公司 | 心衰竭预测组件及心衰竭预测方法 |
| CN112680509A (zh) * | 2021-01-20 | 2021-04-20 | 河南省中医院(河南中医药大学第二附属医院) | 一种评估冠心病预后分子标志物miR-302e及其逆转录引物、扩增引物和应用 |
| CN112904020A (zh) * | 2021-01-25 | 2021-06-04 | 上海市第六人民医院 | Fam172a在筛查和治疗糖尿病大血管病变中的应用 |
| CN112941167A (zh) * | 2021-03-16 | 2021-06-11 | 宁夏医科大学 | 一种心血管疾病诊断用miRNA标志物及其应用 |
| EP4326894A4 (en) * | 2021-04-24 | 2025-06-04 | University of Notre Dame du Lac | Method and device for detection of myocardial infarction and reperfusion injury |
| CN113293207B (zh) * | 2021-06-22 | 2022-09-02 | 上海市东方医院(同济大学附属东方医院) | 外周血miRNA在制备作为心衰诊断或者预后的生物标志物中的用途 |
| JP2024535756A (ja) * | 2021-09-07 | 2024-10-02 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | バイオマーカー組成物およびその使用方法 |
| CN113943792A (zh) * | 2021-11-02 | 2022-01-18 | 石河子大学 | 检测miRNA表达量的试剂在制备诊断或预后哈萨克族高血压的试剂或试剂盒中的应用 |
| CN114388121B (zh) * | 2022-03-25 | 2022-06-03 | 北京盛坤康如医疗器械有限责任公司 | 心脏标志物poct系统及医疗器材 |
| EP4533484A1 (en) * | 2022-06-03 | 2025-04-09 | Foundation Medicine, Inc. | Methods and systems for classification of disease entities via mixture modeling |
| CN114990229B (zh) * | 2022-06-20 | 2023-01-03 | 广东医科大学附属医院 | 一种嗜碱性粒细胞活化相关的生物标志物及其应用 |
| KR20250031367A (ko) * | 2023-08-28 | 2025-03-07 | 고려대학교 산학협력단 | 동맥경화증 진단용 엑소좀 유래 바이오 마커 |
| WO2025135469A1 (ko) * | 2023-12-22 | 2025-06-26 | 서울대학교병원 | 대사질환 예측 또는 진단을 위한 마이크로 rna 바이오마커 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6059724A (en) * | 1997-02-14 | 2000-05-09 | Biosignal, Inc. | System for predicting future health |
| US7888497B2 (en) * | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| US7306562B1 (en) * | 2004-04-23 | 2007-12-11 | Medical Software, Llc | Medical risk assessment method and program product |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| AU2007306594A1 (en) * | 2006-10-09 | 2008-04-17 | Julius-Maximilians-Universitat Wurzburg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
| CA2666817A1 (en) * | 2006-10-19 | 2008-04-24 | Entelos, Inc. | Method and apparatus for modeling atherosclerosis |
| WO2008080126A2 (en) * | 2006-12-22 | 2008-07-03 | Aviir, Inc. | Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| US8768718B2 (en) * | 2006-12-27 | 2014-07-01 | Cardiac Pacemakers, Inc. | Between-patient comparisons for risk stratification of future heart failure decompensation |
| US20090156906A1 (en) * | 2007-06-25 | 2009-06-18 | Liebman Michael N | Patient-centric data model for research and clinical applications |
| BRPI0813527A2 (pt) * | 2007-07-18 | 2014-12-30 | Univ Colorado | Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham |
| US20110160285A1 (en) * | 2008-03-13 | 2011-06-30 | The Regents Of The University Of Colorado | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| CN102047255B (zh) * | 2008-03-26 | 2016-08-03 | 赛拉诺斯股份有限公司 | 医疗信息系统 |
| US8224665B2 (en) * | 2008-06-26 | 2012-07-17 | Archimedes, Inc. | Estimating healthcare outcomes for individuals |
-
2010
- 2010-12-09 WO PCT/US2010/059781 patent/WO2011072177A2/en not_active Ceased
- 2010-12-09 US US12/964,719 patent/US20110144914A1/en not_active Abandoned
- 2010-12-09 AU AU2010328019A patent/AU2010328019A1/en not_active Abandoned
- 2010-12-09 CA CA2783536A patent/CA2783536A1/en not_active Abandoned
- 2010-12-09 EP EP10791032A patent/EP2510116A2/en not_active Withdrawn
- 2010-12-09 CN CN2010800635211A patent/CN102762743A/zh active Pending
- 2010-12-09 JP JP2012543298A patent/JP2013513387A/ja active Pending
-
2015
- 2015-07-01 US US14/788,828 patent/US20150376704A1/en not_active Abandoned
Cited By (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11221340B2 (en) | 2010-07-09 | 2022-01-11 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| US11041866B2 (en) | 2010-08-13 | 2021-06-22 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
| CN107422126A (zh) * | 2011-09-30 | 2017-12-01 | 私募蛋白质体公司 | 心血管危险事件预测及其用途 |
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN103233007A (zh) * | 2013-02-05 | 2013-08-07 | 中国科学院广州生物医药与健康研究院 | hsa-miR-545miRNA及其应用 |
| CN104357554A (zh) * | 2013-11-26 | 2015-02-18 | 上海中医药大学附属岳阳中西医结合医院 | 微小核苷酸has-miR939在高血压诊断中的应用 |
| CN103642914A (zh) * | 2013-11-29 | 2014-03-19 | 李春英 | 与恶性黑素瘤相关的血浆/血清循环microRNA标志物及其应用 |
| CN105993016B (zh) * | 2014-02-04 | 2020-01-10 | 奥普蒂马塔公司 | 用于为具有特定疾病的个体规划医疗的计算机化系统 |
| CN105993016A (zh) * | 2014-02-04 | 2016-10-05 | 奥普蒂马塔公司 | 用于预测医疗效果的方法和系统 |
| CN104017806A (zh) * | 2014-05-08 | 2014-09-03 | 复旦大学 | microRNA及其在制备活动性结核病检测试剂中的应用 |
| US10854314B2 (en) | 2014-05-15 | 2020-12-01 | Codondex Llc | Systems, methods, and devices for analysis of genetic material |
| US11017881B2 (en) | 2014-05-15 | 2021-05-25 | Codondex Llc | Systems, methods, and devices for analysis of genetic material |
| CN104278105A (zh) * | 2014-11-07 | 2015-01-14 | 雷桅 | 一种检测冠心病的血清学生物标志物miR-19a及其用途 |
| CN107710205A (zh) * | 2015-04-14 | 2018-02-16 | 优比欧迈公司 | 用于心血管疾病状况的微生物组来源的表征、诊断和治疗的方法及系统 |
| CN106609301A (zh) * | 2015-10-26 | 2017-05-03 | 北京大学人民医院 | 一种辅助诊断1型糖尿病的试剂盒 |
| CN106609301B (zh) * | 2015-10-26 | 2019-10-25 | 北京大学人民医院 | 一种辅助诊断1型糖尿病的试剂盒 |
| CN105486878A (zh) * | 2016-01-22 | 2016-04-13 | 徐超 | 一种临床个体化组合用药的筛选系统及其方法 |
| CN107194138A (zh) * | 2016-01-31 | 2017-09-22 | 青岛睿帮信息技术有限公司 | 一种基于体检数据建模的空腹血糖预测方法 |
| CN108700596A (zh) * | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
| CN105713972A (zh) * | 2016-03-16 | 2016-06-29 | 上海中医药大学 | miRNA在制备药物性心脏病生物标志物中的用途 |
| CN109416361B (zh) * | 2016-03-31 | 2022-04-19 | 雅培制药有限公司 | 用于估计急性冠状动脉综合征的风险的基于决策树的系统和方法 |
| CN109416361A (zh) * | 2016-03-31 | 2019-03-01 | 雅培制药有限公司 | 用于估计急性冠状动脉综合征的风险的基于决策树的系统和方法 |
| CN110651186A (zh) * | 2017-01-06 | 2020-01-03 | 科多迪克斯有限责任公司 | 用于遗传物质分析的系统、方法和设备 |
| CN110799648A (zh) * | 2017-06-29 | 2020-02-14 | 东丽株式会社 | 用于检测肺癌的试剂盒、装置和方法 |
| CN110799648B (zh) * | 2017-06-29 | 2024-03-22 | 东丽株式会社 | 用于检测肺癌的试剂盒、装置和方法 |
| TWI641963B (zh) * | 2017-07-07 | 2018-11-21 | 長庚醫療財團法人林口長庚紀念醫院 | Method for screening coronary heart disease by cardiovascular marker and mechanical learning algorithm |
| CN109985243B (zh) * | 2017-12-29 | 2021-06-29 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
| CN109985243A (zh) * | 2017-12-29 | 2019-07-09 | 中国科学院上海药物研究所 | 靶向PCSK9的microRNA在治疗LDLC相关代谢性疾病中的应用 |
| CN108004316A (zh) * | 2018-01-09 | 2018-05-08 | 青岛大学 | 用于预测急性心肌梗死风险的试剂盒 |
| CN108376564A (zh) * | 2018-02-06 | 2018-08-07 | 天津艾登科技有限公司 | 基于随机森林算法的疾病诊断并发症识别方法及系统 |
| CN111886630A (zh) * | 2018-02-20 | 2020-11-03 | 密歇根大学董事会 | 用于细胞和亚细胞形态学建模和分类的三维细胞和组织图像分析 |
| CN111886630B (zh) * | 2018-02-20 | 2025-03-04 | 密歇根大学董事会 | 用于细胞和亚细胞形态学建模和分类的三维细胞和组织图像分析 |
| CN108492272B (zh) * | 2018-03-26 | 2021-01-19 | 西安交通大学 | 基于注意力模型及多任务神经网络的心血管易损斑块识别方法及系统 |
| CN108492272A (zh) * | 2018-03-26 | 2018-09-04 | 西安交通大学 | 基于注意力模型及多任务神经网络的心血管易损斑块识别方法及系统 |
| CN108728437A (zh) * | 2018-05-25 | 2018-11-02 | 中国人民解放军陆军军医大学 | 促进骨骼肌损伤修复的寡核苷酸、药物及应用 |
| CN108803994A (zh) * | 2018-06-14 | 2018-11-13 | 四川和生视界医药技术开发有限公司 | 视网膜血管的管理方法及视网膜血管的管理装置 |
| CN108998514A (zh) * | 2018-08-20 | 2018-12-14 | 青岛大学 | miRNA-378及其抑制剂的应用和应用其的产品 |
| CN108998514B (zh) * | 2018-08-20 | 2022-02-01 | 青岛大学 | miRNA-378及其抑制剂的应用和应用其的产品 |
| CN109411015B (zh) * | 2018-09-28 | 2020-12-22 | 深圳裕策生物科技有限公司 | 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质 |
| CN109411015A (zh) * | 2018-09-28 | 2019-03-01 | 深圳裕策生物科技有限公司 | 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质 |
| CN111154870B (zh) * | 2019-08-05 | 2023-06-23 | 江苏省肿瘤医院 | 一种鼻咽癌转移诊断和/或预后评估的生物标记 |
| CN111154870A (zh) * | 2019-08-05 | 2020-05-15 | 江苏省肿瘤医院 | 一种鼻咽癌转移诊断和/或预后评估的生物标记 |
| CN111718991A (zh) * | 2020-07-03 | 2020-09-29 | 西安交通大学医学院第一附属医院 | 血浆miRNA分子标志物在诊断代谢综合征中的应用 |
| CN114058696A (zh) * | 2020-07-29 | 2022-02-18 | 四川大学华西医院 | miR-519e-5p作为甲状腺乳头状癌远处转移检测或治疗靶点中的用途 |
| CN114058696B (zh) * | 2020-07-29 | 2023-08-18 | 四川大学华西医院 | miR-519e-5p作为甲状腺乳头状癌远处转移检测或治疗靶点中的用途 |
| CN114113624A (zh) * | 2020-08-28 | 2022-03-01 | 香港城市大学深圳研究院 | 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置 |
| CN112530595A (zh) * | 2020-12-21 | 2021-03-19 | 无锡市第二人民医院 | 一种基于多分支链式神经网络的心血管疾病分类方法和装置 |
| CN112509700A (zh) * | 2021-02-05 | 2021-03-16 | 中国医学科学院阜外医院 | 稳定型冠心病的风险预测方法及装置 |
| CN115901901A (zh) * | 2022-01-15 | 2023-04-04 | 山东师范大学 | TiO2-MoO3纳米阵列及基于其的miR-145-3p早检传感芯片及其应用 |
| CN116334206A (zh) * | 2022-11-09 | 2023-06-27 | 上海长征医院 | miR-541在制备肝纤维化/肝硬化无创诊断及预后评估试剂盒中的应用 |
| CN117737262A (zh) * | 2024-02-21 | 2024-03-22 | 山东第一医科大学(山东省医学科学院) | 一种miRNA标志物在制备鉴别体液斑产品中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2783536A1 (en) | 2011-06-16 |
| WO2011072177A2 (en) | 2011-06-16 |
| JP2013513387A (ja) | 2013-04-22 |
| US20150376704A1 (en) | 2015-12-31 |
| AU2010328019A1 (en) | 2012-06-28 |
| WO2011072177A3 (en) | 2011-07-28 |
| US20110144914A1 (en) | 2011-06-16 |
| AU2010328019A2 (en) | 2012-06-28 |
| EP2510116A2 (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102762743A (zh) | 用于心血管疾病的诊断和分类的生物标记物检验 | |
| DeTomaso et al. | Hotspot identifies informative gene modules across modalities of single-cell genomics | |
| Lusardi et al. | MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer’s disease | |
| Simon et al. | Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification | |
| US20240194294A1 (en) | Artificial-intelligence-based method for detecting tumor-derived mutation of cell-free dna, and method for early diagnosis of cancer, using same | |
| CN107102151A (zh) | 心血管危险事件预测及其用途 | |
| US20040158581A1 (en) | Method for determination of co-occurences of attributes | |
| US9020934B2 (en) | Method, an arrangement and a computer program product for analysing a biological or medical sample | |
| Li et al. | scImpute: accurate and robust imputation for single cell RNA-seq data | |
| Schneider et al. | Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma | |
| Wu et al. | Construction of novel gene signature-based predictive model for the diagnosis of acute myocardial infarction by combining random forest with artificial neural network | |
| Dunkler et al. | Statistical analysis principles for Omics data | |
| de Gonzalo-Calvo et al. | Plasma microRNA profiling reveals novel biomarkers of epicardial adipose tissue: a multidetector computed tomography study | |
| Zhang et al. | Atherosclerotic plaque vulnerability quantification system for clinical and biological interpretability | |
| JP2024544749A (ja) | 細胞遊離核酸断片の位置別配列頻度及びサイズを用いたがん診断方法{Method for detecting cancer using fragment end sequence frequency and size by position of cell-free nucleic acid} | |
| Acedera et al. | Age, comorbidities, c-reactive protein and procalcitonin as predictors of severity in confirmed COVID-19 patients in the Philippines | |
| Jia et al. | A biological age model based on physical examination data to predict mortality in a Chinese population | |
| CN121002198A (zh) | 用于鉴别一种或多种预测性生物标志物的人工智能 | |
| CN118879858A (zh) | 一组用于预测非小细胞肺癌放疗预后的基因标签及应用 | |
| Bérubé et al. | A Bayesian hierarchical model for signal extraction from protein microarrays | |
| Jardillier et al. | Benchmark of lasso-like penalties in the Cox model for TCGA datasets reveal improved performance with pre-filtering and wide differences between cancers | |
| Reddy et al. | Real-time data mining-based cancer disease classification using KEGG gene dataset | |
| Wang et al. | Improved estimation of cell type-specific gene expression through deconvolution of bulk tissues with matrix completion | |
| US20130073213A1 (en) | Gene Expression-Based Differential Diagnostic Model for Rheumatoid Arthritis | |
| US20250046451A1 (en) | Generative Adversarial Network for Urine Biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121031 |